Pharmaceutical firm Ark Therapeutics has appointed Russell Banks as chief financial officer (CFO). Banks has been selected for the role following the departure of predecessor David Bowyer, who has chosen to take up a new position at a company based in his native Zimbabwe.
Banks previously served as the European finance director for medical company Cephalon for more than a decade, playing a key role in the business’ growth during this period.
A report by broking group Marsh examines the repercussions from the administration of the South Korean company, which filed for bankruptcy protection at the end of August.
Global research by C2FO suggests that smaller businesses are less concerned with the repercussions of Brexit and the upcoming US presidential election.
A squeeze on skilled talent means it now takes an average of seven weeks to fill open permanent roles in finance in the UK according to new research from financial services recruitment firm Robert Half.
Early-stage merger and acquisition deals in Asia-Pacific show nearly 10% year-on-year growth in recent months.